SYNOPSIS A method is described whereby about 100 litres of plasma containing 10-50 IU/ml tetanus antitoxin was obtained, from which were prepared 5000 x 250 IU doses of human antitetanus immunoglobulin. Of 40 blood donors who received a booster injection of tetanus vaccine BP, 33 were plasmapheresed each week over a 10-12 week period starting three weeks after the injection. Twenty-two of these donors provided 90% of the total plasma, the antitoxin content of which averaged 23-6 IU/ml over the 10-12 week period.
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The adverse reactions of patients to horse tetanus antitoxin and the possible medicolegal repercussions for any doctor using this therapy are now well known. Consequently, human antitetanus immunoglobulin (ATIG) is now gaining widespread acceptance. It has been used solely for at least 10 years at the Johns Hopkins Hospital, Baltimore (Shirkey, 1965) and has been available for a similar time in Canada (Perey, 1966) , Australia, Switzerland, and Sweden. In the United Kingdom, ATIG is usually restricted to casualties whose previous tetanus immunity is in doubt, and/or in whom complete debridement of the wound may not be advisable, and/or in whom there is demonstrable evidence of hypersensitivity to heterologous protein. Its use is combined with an injection (0 5 ml-20 Lf) of adsorbed tetanus vaccine BP (TT ads). The main advantage is that ATIG is free of the anaphylactic reactions resulting from horse antitoxin. The 250 unit dose of ATIG reliably gives a protective antitetanus level (over 0-01 unit/ml) for about four weeks. This product should also be effective in clinical situations where antibiotic therapy would be unsuitable, eg severe wounds, those seen late after injury or those with a secondary infection, and in the treatment of cases of established tetanus where it could be used intravenously combining (a) rapidity of effect, (b) safety, and (c) maintenance of effective blood levels.
In Scotland, the five Regional Transfusion Centres are normally self-supporting in the supply of blood and blood products. Commercial blood products are rarely used as such items are supplied by the Protein Fractionation Centre at Edinburgh.
Received for publication 5 August 1975 The need to find a suitable source of high-titre plasma for the production of ATIG stimulated a search among various donor groups.
The following were approached: 1 Service personnel Figure 2 shows the antitoxin levels of some 40 donors 3, 6, 10, 12, and 14 weeks following a booster injection of TT (simple). These donors were divided into five groups-< 10, 10-20, 20-50, 50-80, and 80+ IU/ml, according to the antitoxin level found at these times. In 21 of these donors the concentration was less than 10 IU/ml by the eighth week but in a further 10 averaged 20-50 IU/mi in the twelfth week. In six of these donors the concentration exceeded 50 IU/ml in the first six weeks after injection. The notable response in one of these donors is shown in figure 3 . This donor had a pre-injection level of less than 5 IU/ml, but accurate assays of the pre-injection levels in the 40 donors were not done as previous experience had shown that less than 5 % would be above 1 IU/ml. Wilson (1967) found an average level of 0 7 IU/ml in a blood donor clinic. Accordingly, our assay system was set to detect only those with more than 10 IU/mi, ie, those in whom a relatively high titre of [10] [11] [12] Previous data showed that less than 5 % of unweek period of plasmapheresis.
selected donors had an antitoxin concentration above 10 IU/ml. Sgouris et al (1966) found that Discussion 2-8 % of unselected donors had levels of 10-20 IU/ml. Entwistle and Eldridge (1973) reported that Before the development of immunological tests, 1-5% of East Anglian donors had more than such as immunodiffusion and immunoelectro-10 IU/ml, and Nelson (1973) observed that 25-35% of Swiss Army recruits had concentrations over 5 IU/ml after a second booster. Billaudelle (1967) , working in Sweden, observed that approximately the same concentration of antitoxin is evoked by each booster injection so that the same group of selected donors may be used as a source of plasma for many years. Similar findings were reported from Russia where Papko et al (1970) showed that 16 7% reached 15-20 IU/ml after a dose of 30 units of tetanus toxoid and that doses of 50 and 100 units of TT produced concentrations of at least 50 IU/ml in 34-52% of subjects.
The response to TT ads is superior to that produced by TT (simple) (Chernaya and Kovtunovich, 1963) , and it is probable that peak levels in our donors would have been still more impressive if adsorbed toxoid had been used. The risk of local and general reactions to TT increases with the frequency of the booster injections (British Medical Journal, 1974) . For this reason and because we plan to invite these donors to revolunteer, say every fourth year, we decided not to use TT ads for the initial booster dose. By so doing we hope to reduce the number of reactions in later years. It remains to be seen whether a second group boosted with TT ads will show more reactions in three to five years when reboosted.
The use of plasmapheresis enabled us to collect from 33 donors within 14 weeks of a single booster injection over 100 litres of high-titre antitetanus plasma from which would be prepared 5000 x 250 IU prophylactic doses, or a smaller number of 5000 or 7500 IU doses for treatment. Although a minimum level of 2 IU/ml is acceptable for fractionation, the protective dose of 250 IU (at 10% protein concentration) is then contained in 5 0 ml of immunoglobulin. The higher concentration of antitoxin obtained by the above method permits the dose volume to be much reduced. 
